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Summary 
We investigated the role of interleukin 8 (IL-8) in mediating angiogenesis in human bronchogenic 
carcinoma. Increased quantities of IL-8 were detected in tumor tissue as compared with normal 
lung tissue.  Immunohistochemical staining of tumors revealed primary localization of IL-8 to 
individual tumor cells and demonstrated the capacity of tumor to elaborate IL-8.  Functional 
studies that used tissue homogenates of tumors demonstrated the induction of both in vitro 
endothelial cell chemotaxis and in vivo corneal neovascularization. It is important to note that 
the addition of neutralizing antisera  to IL-8 to these assays resulted in the marked and specific 
attenuation of these responses. Our observations definitively  establish IL-8 as a primary mediator 
of angiogenesis in bronchogenic carcinoma and offer a potential target for immunotherapies against 
solid malignancies. 
T 
he leading cause of malignancy-related mortality in the 
United States is bronchogenic carcinoma (1). While the 
incidence of many other malignancies has declined or remained 
stable,  the occurrence of bronchogenic carcinoma has esca- 
lated to near-epidemic proportions. Over 150,000 new cases 
are diagnosed and an equal number of deaths are attributable 
to bronchogenic carcinoma in the U.S. annually (1). Despite 
attempts to advance early diagnosis and employ combination 
therapies,  the clinical response of this tumor yields an overall 
5-yr survival rate for lung cancer patients of <15%. A new 
approach to therapy is dearly needed. 
Tumor vascularization is crucial for the pathogenesis of 
all  solid  malignancies.  In  the  absence  of local  capillary 
proliferation,  tumors  may not  grow beyond 2-3  mm  in 
diameter (2).  Folkman first proposed in 1972 that tumors 
are angiogenesis-dependent, with tumor growth requiring 
concomitant increases in vascular supply. Previous studies have 
attempted to investigate the complexities of tumor neovas- 
cularization (3). Certain tumors have been found to produce 
factors that are directly angiogenic, whereas others may de- 
pend upon vascularization induced by products of responding 
inflammatory cells (4-6).  IL-8 is a cytokine of the C-X-C 
supergene family that has been classified primarily by pro- 
inflammatory and leukocyte chemotactic properties (7-9). A 
variety  of  cell  populations,  including  neutrophils  (10), 
mononuclear (11, 12), stromal (13), endothelial (14), and ep- 
ithelial cells (15), and hepatocytes (16) may serve as sources 
for IL-8. The recent characterization of potent angiogenic 
properties has renewed interest in the role of IL-8 in a variety 
of settings (17, 18). In the present study we demonstrate IL-8 
is a primary mediator of angiogenesis in human broncho- 
genic carcinoma. 
Materials and Methods 
Antigenic Determination of lL-8 Content of  Normal Lung and Bron- 
chogenic Tumor Tissue.  Tissue  specimens were obtained from con- 
senting individuals undergoing thoractomy for suspected primary 
bronchogenic carcinoma in  accordance with the  University of 
Michigan  I.R.B. approval. Samples  of tumor, and normal lung distal 
to tumor, were homogenized in PBS upon recovery  from the oper- 
ating room.  Specimens were then filtered through 0.45-micron 
Sterile Acrodiscs (Gelman Sciences Inc., Ann Arbor, MI) and frozen 
at  -70~  until thawed and then assayed. A specific ELISA for 
Ib8 was employed to determine IL-8 content of tissue samples as 
previously  described (19). Samples  were run in parallel for total pro- 
tein content (Pierce Chemical Co., Rockford, IL). Determinations 
were expressed as nanograms of I1.,8 per milligrams total protein. 
Results were tabulated based on final histological diagnosis as de- 
termined by University Hospital pathologists. 
Immunohistochemical Localization of Antigenic IL-8. Fresh tissue 
specimens obtained at time of thoractomy were fixed in 4% para- 
formaldehyde  for 24 h before transferring to 70% ethanol. Paraffin- 
embedded tissue sections were dewaxed  with xylene and rehydrated 
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for IL-8 using a modification of our previously described technique 
(20). Briefly, nonspecific binding sites were blocked with normal 
goat  serum  (BioGenex Laboratories,  San  Ramon,  CA)  before 
washing and applying a  1:1,000 concentration of either control 
(rabbit) or rabbit anti-human IL-8 serum. Slides were then rinsed 
and overlaid with secondary biotinylated goat anti-rabbit IgG (1:35) 
and then incubated. After washing twice with Tris-buffered saline, 
slides were overlaid with a 1:35 dilution of alkaline phosphatase 
conjugated to streptavidin (BioGenex Laboratories), and incubated. 
Fast Red (BioGenex Laboratories) reagent was used for chromo- 
genic localization of Ib8 antigen. After optimal color development, 
sections were immersed in sterile water, counterstained with Mayer's 
hematoxylin, and coverslipped using an aqueous mounting solution. 
Endothelial Cell Chemotaxis Responses to IL.8 Standard and Tissue 
Specimens.  Endothelial cell chemotaxis was performed in 48-well, 
blind well chemotaxis chambers (Nucleopore Corp., Pleasanton, 
CA) as previously described (21). Nucleopore Chemotaxis mem- 
branes (5 micron pore size; Nucleopore Corp.) were prepared by 
soaking them sequentially in 3% acetic acid overnight and for 2 h 
in 0.1 mg/ml gelatin. Membranes were rinsed in sterile water, dried 
under sterile air, and stored at room temperature for up to 1 too. 
Bovine adrenal gland capillary endothelial cells (BCE), 1 maintained 
in gelatin-coated flasks in DME with 10% FCS were used as the 
target cells. 24 h before use BCE were starved in DME with 0.1% 
BSA. 25 #1 of cells, suspended  at a concentration of 106 per ml 
in DME with 0.1% BSA were dispensed into each of the bottom 
wells. A chemotaxis membrane was positioned atop the bottom 
wells, chambers were sealed, inverted, and incubated for 2 h to allow 
cells to adhere to the membrane. Chambers were then reinverted, 
50/~1 test media was dispensed into the top wells and reincubated 
for an additional 2 h. Membranes were then fixed and stained with 
a Dill-Quick staining kit (American Scientific Products, McGraw 
Park, IL) to enumerate membrane-bound cells, and cells that had 
migrated  through  the  membrane  to  the opposite surface  were 
counted. Four replicates,  10 fields/replicate,  were tested for each 
sample, and experiments were repeated at least three times. Results 
were expressed as the total number of endothelial cells that migrated 
across the filter in 10 high power (400 x) fields. IL-8 neutralization 
studies  used our previously well-characterized  polyclonal rabbit 
anti-human IL-8 antibody (13, 18, 20). Additional neutralization 
studies  employed  the  commercially available  neutralizing  goat 
anti-human TGF-c~ antibody and rabbit anti-basic fibroblast growth 
factor (bFGF) (R&D Systems,  Minneapolis,  MN). 
Corneal Micropocket Model of Angiogenesis.  In vitro angiogenic 
activity was assayed in the avascular cornea of F344 female rats eyes, 
as previously described (22, 23). Briefly, 5 mg total protein of each 
specimen  was combined with a equal volume of sterile  Hydron 
casting solution, and 5-ml aliquots were pipetted onto the surface 
of l-ram Teflon rods glued to the surface of a glass petri dish. Pellets 
were air-dried  in a laminar flow hood (1 h) and refrigerated over- 
night. Before implantation pellets were rehydrated with a drop of 
lactated Ringer's solution. Animals were anesthetized with meto- 
lane and injected with sodium pentobarbital intraperitoneally. A 
retrobulbar injection of 0.1 ml of 2% lidocaine was made before 
intracorneal implantation of the Hydron pellet into a surgically 
created intracomeal pocket "~1.5 mm from the limbus. The animals 
were examined daily with a stereomicroscope.  7 d after implanta- 
tion, animals were reanesthetized and perfused sequentially  with 
1 Abbreviations used in this paper: BCE, bovine adrenal gland capillary 
endothelial cells; bFGF, basic fibroblast growth factor; TP, total protein. 
lactated Ringer's solution followed by colloidal carbon. Corneas 
were harvested, flattened, and photographed (33 x). Positive neo- 
vascularization responses were recorded only if sustained directional 
ingrowth of capillary  sprouts and hairpin loops towards the im- 
plant were observed. Negative responses were recorded when ei- 
ther no growth was observed or when only an occasional sprout 
or hairpin loop displaying  no evidence of sustained  growth was 
detected. Animals were handled in accordance with the University 
of Michigan U.L.A.M.  protocols. 
Results and Discussion 
IL-8 Is Increased in  Tumor Tissue.  We began our evalua- 
tion using an ELISA to detect IL-8 in human tissue homo- 
genates of both normal lung and nonsmall cell bronchogenic 
carcinomas. As shown in Fig. 1, antigenic IL-8 was observed 
in a fourfold excess in tumor tissue as compared with normal 
lung tissue (expressed as nanograms per milligrams of total 
protein [TP]). Normal lung tissue contained 2.604  _+ 0.729 
ng/mg TP oflL-8, as compared with 8.499  _+ 2.327 ng/mg 
TP for tumor samples (n  =  52).  There were similar eleva- 
tions of antigenic IL-8 for tumors of adenocarcinoma histology 
as compared with those of squamous cell phenotype, 6.986  + 
3.314 ng/mg TP and 9.752  _+ 2.956 ng/mg TP, respectively. 
Immunohistochemistry Localizes IL-8 to Individual Tumor Cells. 
We next used immunohistological localization to demonstrate 
the cellular origins of antigenic IL-8 in tumor tissue. Previous 
studies have convincingly demonstrated  that human bron- 
chogenic tumor cell lines may directly elaborate IL-8 (20, 
24). We exploited immunohistochemical localization to iden- 
tify cellular sources of the increased IL-8 in  tumor tissue. 
Stains of tumor sections typically demonstrate heterogeneous 
tumor cell production of IL-8 in both adenocarcinomas and 
squamous cell carcinomas of the lung (Fig. 2). In addition, 
our  results  reveal that  stromal  cells  within  the  local des- 
moplastic response may also serve as cellular sources for IL-8, 
especially in squamous cell cardnomas. It is important to note 
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Figure  1.  IL-8  content of tissue samples of normal lung and broncho- 
genic lung tumors. Subgroup analysis by tumor histological diagnosis. 
1410  Inhibition of II.-8 Attenuates Angiogenesis in Bronchogenic Carcinoma Figure  2.  Immunohistochemical 
staining of 1I.-8 in tumor tissue.  (A) 
Normal lung with preimmune serum 
(200 x). (B) Normal lung with anti-IL-8 
(200 x). (C) Squamous  cell carcinoma 
with preimmune serum (200 x). (D, E, 
and F) Squamous cell carcinoma with 
anti-lL-8 antibody (100, 200, and 400x, 
respectively). (G) Adenocarcinoma with 
preimmune serum (200 x). (/4, I,J) Ad- 
enocarcinoma  with anti-IL-8 antibody 
(100, 200,  and 400￿  respectively). 
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clinical behaviors of squamous cell and adenocarcinomas. The 
more aggressive course of adenocarcinomas  could result from 
its capacity to generate suf~cient angiogenic signal by tumor 
IL-8 production, independent from contributions from the 
surrounding tissue response.  The observation of a minimal 
inflammatory  cell infiltrate in the tumor samples, despite the 
presence of significant quantities of IL-8, is unexpected and 
of particular interest. 
Endothelial Cell Chemotaxis Activity to Tumor Homogenates 
Is Blocked by Anti-IL-8.  To determine the relative contribu- 
tion of IL-8 to the total angiogenic signal  from broncho- 
genic carcinomas we employed a strategy using both in vitro 
and in vivo models of angiogenesis.  First, concentrated tissue 
homogenates from normal lung, adenocarcinoma, and squa- 
mous cell carcinomas,  as well as tissue extracts from suspen- 
sions of a bronchoalveolar carcinoma cell line (ATCC-A549; 
American Type Culture Collection, R.ockville, MD), were 
evaluated for chemotactic activity toward BCE. Results for 
tissue samples were expressed as a percentage of chemotaxis 
activity induced by a standard of 50 ng/ml recombinant human 
IL-8. As illustrated in Fig. 3 A, samples  from adenocarci- 
noma, squamous cell carcinoma, and A549 cells demonstrated 
62, 84, and 86% respectively, of the maximal BCE chemotaxis 
induced by the IL-8 standard. BCE chemotaxis in response 
to media alone was 16% of the IL-8 standard. The addition 
of neutralizing antibodies to IL-8 reduce the endothelial cell 
chemotactic response  to each of the test samples by '~66% 
(to a background level of 33% of the standard activity) (13, 
20). Specifically,  BCE chemotaxis in response to tissue samples 
plus anti-IL-8 was attenuated to similar background levels 
of 37, 39, and 32% of the standard, respectively, for adeno- 
carcinoma, squamous cell carcinoma, and A549 tissue  and 
cell homogenates. This data suggested that a significant por- 
tion of tumor-generated endothelial cell chemotaxis is medi- 
ated directly by IL-8. To further examine the angiogenic signal 
from tumor specimens in an attempt to characterize the rela- 
tive contributions of other known angiogenic factors  such 
as bFGF and TGF-cr  a second series of experiments were 
performed. Endothelial cell chemotactic studies were repeated 
as before, with addition of neutralizing antibodies to either 
IL-8, bFGF, or TGF-o~. Results are demonstrated in Fig. 3 
B, standardized to the response  generated from a standard 
of 25 ng/ml bFGE Normal lung tissue generated only 40% 
of standard chemotactic activity, and was not significantly 
affected by the addition of any of the neutralizing antisera. 
Again, tumor samples alone generated brisk chemotactic re- 
sponses, with 198, 130, and 104%  standard activity, respec- 
tively, for samples of adenocarcinoma, squamous cell carci- 
noma, and A549 cell line tissue. The addition of neutralizing 
antibodies to IL-8 again resulted in significant reductions of 
chemotactic responses to tumor tissue, with decreases to 75, 
39, and 61% standard activity, respectively,  for adenocarci- 
noma, squamous cell carcinoma, and A549 samples.  Anti- 
bFGF antibodies had no significant effect on responses  to 
samples of A549 or squamous cell carcinoma tissue, but did 
yield a reduction in chemotactic activity of adenocarcinoma 
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Figure 3.  Endothelial  cell  chemotaxis.  (A) Demonstrates  responses stan- 
dardized to 50 ng/ml IL8, of specimens  of normal  lung, adenocarcinomas, 
squamous cell carcinomas, and A549 tissue in the presence or absence of 
specific neutralizing  antisera to Ib8. Also demonstrates  response to pro- 
rein control. (B) Endothelial  cell  chemotactic  responses to normal  and tumor 
tissue, standardized  to 25 ng/ml bFGF. Effect  of addition of specific  neu- 
tralizing antisera to IL-8, bFGF, and TGF-~ is also demonstrated. 
tissue from 198 to 137%  standard activity. It is interesting 
to note that the neutralization of TGF-o~ effected no change 
in responses to adenocarcinoma or A549 tissue, but demon- 
strated a significant reduction in the chemotactic response 
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dard  activity. 
Neovascularization Induced by Tumor Homogenates Is Attenu- 
ated by Anti-IL-8.  We next evaluated the angiogenic signal 
mediated by tumor-associated IL-8 in an in vivo model. The 
previously well-characterized corneal micropocket modal in 
the rat was employed (22, 23). Tissue samples and controls 
were incorporated into Hydron (Interferon Sciences Inc., New 
Brunswick, NJ) pellets and then embedded into the normally 
avascular  rat  cornea (Fig.  4  and Table 1).  Control  samples 
of either 50 ng recombinant IL-8 or 50 ng recombinant bFGF 
induced positive corneal angiogenic responses of 80 and 100%, 
respectively. Samples from normal lung, adenocarcinoma,  squa- 
mous cell carcinoma samples, and A549 cells produced posi- 
tive angiogenic responses in 13 (1/8), 86 (6/7), 83 (5/6), and 
100%  (7/7),  respectively. Anti-IL-8  antibodies  completely 
abrogated the angiogenic response to IL-8 controls (zero of 
four corneas positive), but had no effect upon angiogenesis 
induced by bFGF (three of three corneas positive). The addi- 
tion  of antibodies to IL-8 resulted in significant  reduction 
of angiogenic responses to tumor tissue samples.  A549 cell 
homogenates, which had yielded a 100% neovascularization 
rate,  demonstrated no angiogenic activity in the presence of 
neutralizing antibodies to IL-8 (zero of five samples positive). 
Neutralizing antibodies to IL-8 caused a reduction in tumor 
sample angiogenesis of both adenocarcinoma and squamous 
cell carcinoma with 80% (four of five) and 80% (four of five) 
inhibition of angiogenesis, respectively.  The addition of anti- 
IL-8 antibodies to normal lung samples did not induce a posi- 
tive  angiogenic  response  (zero  of four  positive),  whereas 
normal lung samples with control antibodies had a 17% posi- 
tive angiogenic response (one of six positive). It is important 
to note that  there was no infiltration  of the corneal  tissue 
by inflammatory cells in any of the test samples or controls, 
suggesting that the angiogenic responses were mediated en- 
tirely by factors present in tumor tissue, rather than by any 
additional contributions from infiltrating inflammatory cell 
products. 
Figure  4.  In vivo angiogenesis demonstrating inhibition of lung tumor extract-induced corneal neovascularization by IL-8 neutralizing antibody. 
Representative photomicrographs of corneal neovascular  responses. (A) Positive  angiogenic response  induced by A549 cellular homogenate. (B) Positive 
angiogenic response  induced  by tissue homogenate  from human bronchogenic squamous  cell  carcinoma. (C) Negative angiogenic response  from normal 
lung homogenate. (D) Markedly  suppressed  angiogenic response  induced  by squamous  cell  carcinoma tissue  homogenate  preincubated  with neutralizing 
IL-8 antibody. 
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Proportion of positive responses 
Test sample  (-) anti-IL-8 Ab  (+) anti-IL-8 Ab 
Controls 
HBSS  0/3  (0)  0/4 (0) 
IL-8 (50 ng)  4/5 (80)  0/4 (0) 
bFGF (25 ng)  3/3 (100)  3/3 (100) 
Lung Tissue 
Normal lung  1/6 (17)  0/4 (0) 
Squamous cell  2/3 (66)  1/5  (20) 
carcinoma 
Adenocarcinoma  3/4 (75)  1/5  (20) 
A549 cell line  4/4 (100)  0/5 (0) 
Composite  of data demonstrating  inhibition  of lung tumor extract-induced 
corneal neovascularization  by IL-8 neutralizing antibody. 
These studies demonstrate that a primary angiogenic signal 
for bronchogenic carcinoma neovascularization is  directly 
mediated by tumor-associated IL-8. Other previously described 
factors appear to also be involved to a lesser extent in tumor 
angiogenesis, with perhaps some variation by tumor histology. 
Although previous  studies have demonstrated that various 
tumors and tumor cell lines elaborate  IL-8, the significance 
of tumor production of a neutrophil chemotaxin remained 
enigmatic (16, 20, 24-27).  Our data, coupled with the re- 
cent characterizations  of IL-8 bioactivity, suggest that tumor 
production of this potent angiogenic factor may be crucial 
for the neovascularization necessary for the initiation and main- 
tenance of tumor growth. Interestingly, other investigations 
have noted increased angiogenic activity in hyperplastic le- 
sions which precedes subsequent malignant transformation, 
suggesting that increased IL-8 production may play a func- 
tional role  in, or possibly serve as a marker for,  cytogenic 
dysregulation (28, 29). The observation of minimal inflam- 
matory cell infiltrate, despite an appropriate chemotactic signal, 
remains perplexing and may reflect the attenuation of inflam- 
matory cell chemotactic signal by other tumor-derived factors. 
Our recent  description of the production of IL-1  receptor 
antagonist protein by human bronchogenic carcinoma lends 
support to this concept (30). Finally, as the demand for fur- 
ther vascular supply increases with continued tumor growth, 
successful maintenance of vascularization  may require exploi- 
tation of normal inflammatory responses in order to provide 
adequate angiogenic signal. Accordingly, tumors may also 
elaborate  additional factors  to  stimulate or  enhance  IL-8 
production by other cells in a paracrine fashion, which may 
be reflected in the immunohistochemical localization of IL-8 
in stromal cells within the tumor matrix. Future studies will 
explore the consequences of  attenuation of tumor IL-8 produc- 
tion as a possible therapeutic intervention for bronchogenic 
carcinoma. 
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